Download PDF
Digestive Disease Interventions 2024; 08(03): 173-182
DOI: 10.1055/s-0044-1788691
Review Article

Current Trends in Hepatocellular Carcinoma Therapies in China

Authors

  • Ying Zhang   *

    1   Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China
    2   Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

  • Yong Wang   *

    1   Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China
    2   Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

  • Jin-He Guo 

    1   Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China
    2   Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

  • Jian Lu 

    1   Department of Radiology, Center of Interventional Radiology and Vascular Surgery, Zhongda Hospital, Medical School of Southeast University, Nanjing, China
    2   Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China

Funding The study was supported by Jiangsu Provincial Special Program of Medical Science (BE2022855), ZhiShan Scholar Program of Southeast University (2242022R40069), and National Key Research and Development Program (2018YFA0704100, 2018YFA0704104) and Research Personnel Cultivation Programme of Zhongda Hospital Southeast University (CZXM-GSP-RC124). The funders of the article had no role in the study protocol design, data analysis, interpretation, or manuscript writing.
Further Information
Also available at
   Permissions and Reprints
Preview

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor that is particularly prevalent in China, making up almost 50% of HCC cases worldwide. Compared to HCC patients in Europe, North America, and the Asia-Pacific region, Chinese patients exhibit unique characteristics in etiology, demographics (age, gender, geographic location, economic status), biological behavior, treatment options, and prognosis. While hepatitis B virus remains a primary cause of HCC in China, there is a growing trend of alcoholic liver disease and nonalcoholic fatty liver disease in the country. A special pathological staging guidance distribution of therapies for HCC was developed by the Chinese Medical Association. In China, there is a diverse array of therapeutic options for treating HCC, including liver resection, liver transplantation, intra-arterial therapies, ablation, radiotherapies, systemic therapies, and traditional Chinese medicine. The treatment of HCC has multiple permutations and combinations of modalities. Due to the varying stages of HCC and individual patient differences, the multidisciplinary team model is often necessary to tailor treatment strategies and optimize clinical outcomes. Meanwhile, to enhance survival benefits and effectively improve the prognosis and life quality of patients with HCC, Chinese experts are actively engaged in conducting clinical trials to identify potential beneficiary populations. This review aims to elaborate on the therapeutic features of HCC in China to present to the world the innovative approaches and comprehensive care offered to Chinese HCC patients.

Keywords

hepatocellular carcinoma - therapies - multidisciplinary team

* Contributed equally as joint first authors.




Publication History

Article published online:
26 August 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA